Arizona State University/Halberd Initiate Patent Application for Unique New Engineered Class of Covid-19 Antibody

Rhea-AI Summary

Halberd Corporation (OTC PINK: HALB) has announced the development of a new class of anti-Spike protein monoclonal antibodies targeting Covid-19, in collaboration with Arizona State University. They are in the process of filing joint patent applications for this discovery. The engineered antibodies may enable rapid detection of the virus in various samples and on surfaces. This advancement aims to enhance early identification and treatment, potentially curbing the virus's spread. Halberd's CTO highlighted the progress, signaling more patent applications to follow.

Positive

• Development of a new class of anti-Spike protein monoclonal antibodies against Covid-19.
• Collaborative research with Arizona State University indicates strong scientific backing.
• Potential for rapid virus identification could enhance public health response.
• Patents being filed may protect intellectual property and generate future revenue.

Negative

• Pending patent applications introduce uncertainty regarding competitive advantage.
• The ultimate impact of Covid-19 on operations remains unknown, creating investment risk.

JACKSON CENTER, PA / ACCESSWIRE / October 19, 2020 / Halberd Corporation (OTC PINK:HALB) today announced the creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19. The discovery is the result of Halberd's research in conjunction with Arizona State University's Dr. Qiang "Shawn" Chen, utilizing Halberd's intellectual property created by Mitchel S. Felder, MD. Halberd and ASU have begun the process of filing the first of multiple planned joint patent applications for this new class of antibody.

This engineered monoclonal antibody against the Covid-19 virus spike protein may allow for an extremely rapid identification of the Covid-19 virus in nasal mucus, saliva, and blood. It may also potentially allow for the rapid identification of the Covid-19 virus present on surfaces, such as food, cell phones, door handles, etc., through testing only a small sample. Details concerning this rapid identification methodology will not be publicly disclosed until appropriate patent protections are in place. Halberd scientists believe that this breakthrough may help solve the Covid-19 pandemic by accelerating the identification of the Covid-19 virus, and the scientific analysis of the effectiveness of Covid-19 therapeutics.

Scientists from Halberd believe that rapid identification is essential to permit effectively initiating therapeutics in the earliest phases of Covid-19. Early identification and treatment could substantially curtail the spread of COVID-19.

Dr. Patricio Reyes, Chief Technical Officer of Halberd Corporation, stated, "The progress over the past month has been phenomenal and is already yielding patentable intellectual property. We foresee this as just the first of many potential patent applications to address the rapid detection, prevention, and treatment of Covid-19."

The details of the Halberd-ASU research contract can be viewed here.

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
Twitter:@HalberdC

About Arizona State University.

Arizona State University, ranked No. 1 "Most Innovative School" in the nation by U.S. News & World Report for six years in succession, has forged the model for a New American University. ASU is a comprehensive public research institution, measured not by whom it excludes, but by whom it includes and how they succeed; advancing research and discovery of public value; and assuming fundamental responsibility for the economic, social, cultural and overall health of the communities it serves. ASU operates on the principle that learning is a personal and original journey for each student; that they thrive on experience, and the process of discovery cannot be bound by traditional academic disciplines. Through innovation and a commitment to accessibility, ASU has drawn pioneering researchers to its faculty even as it expands opportunities for qualified students, attracting some of the highest caliber students from all 50 states and more than 130 nations.

About Halberd Corporation.

Halberd Corporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd's Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company's Articles of Incorporation here. The number of outstanding shares remains at 317,721,539.

The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus", and, "Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/611073/Arizona-State-UniversityHalberd-Initiate-Patent-Application-for-Unique-New-Engineered-Class-of-Covid-19-Antibody

FAQ

What is Halberd Corporation's recent announcement regarding Covid-19?

Halberd Corporation announced the development of a new class of anti-Spike protein monoclonal antibodies against Covid-19, in collaboration with Arizona State University.

What potential benefits do Halberd's new antibodies offer?

The antibodies could enable rapid identification of the Covid-19 virus in nasal mucus, saliva, and blood, potentially improving treatment initiation and curtailing the virus's spread.

Is Halberd Corporation working on any patents for their new Covid-19 antibodies?

Yes, Halberd Corporation is in the process of filing multiple joint patent applications for the new class of antibody.

How does Halberd Corporation ensure compliance with regulatory bodies?

Halberd Corporation is in full compliance with OTC Market reporting requirements and has provisions in its Articles of Incorporation to prevent dilution.

What are the risks associated with Halberd Corporation's Covid-19 initiatives?

There are risks pertaining to the unknown impact of the Covid-19 pandemic on operations, as well as the uncertainties around pending patents and market competition.